RT Journal Article
T1 A Genome-Wide Association Study on Liver Stiffness Changes during Hepatitis C Virus Infection Cure
A1 Corma-Gómez, Anaïs
A1 Macías, Juan
A1 Rivero, Antonio
A1 Rivero-Juarez, Antonio
A1 de Los Santos, Ignacio
A1 Reus-Bañuls, Sergio
A1 Morano, Luis
A1 Merino, Dolores
A1 Palacios, Rosario
A1 Galera, Carlos
A1 Fernández-Fuertes, Marta
A1 González-Serna, Alejandro
A1 de Rojas, Itziar
A1 Ruiz, Agustín
A1 Sáez, María E.
A1 Real, Luis M.
A1 Pineda, Juan A.
K1 GWAS
K1 Hepatitis C virus infection
K1 Polymorphisms
K1 Sustained virological response
K1 Direct-acting antivirals
K1 Liver stiffness
K1 Chromatin
K1 DNA Packaging
K1 Estudio de asociación del genoma completo
K1 Hepatitis C
K1 Hepacivirus
K1 Polimorfismo de nucleótido simple
K1 Antivirales
K1 Cromatina
K1 Empaquetamiento del ADN
AB Liver stiffness (LS) at sustained virological response (SVR) after direct-acting antivirals (DAA)-based therapy is a predictor of liver events in hepatitis C virus (HCV)-infected patients. The study aim was to identify genetic factors associated with LS changes from the moment of starting anti-HCV therapy to SVR. This prospective study included HCV-infected patients from the GEHEP-011 cohort who achieved SVR with DAA-based therapy, with LS pre-treatment ≥ 9.5 kPa and LS measurement available at SVR. Plink and Magma software were used to carry out genome-wide single-nucleotide polymorphism (SNP)-based and gene-based association analyses, respectively. The ShinyGO application was used for exploring enrichment in Gene Ontology (GO) categories for biological processes. Overall, 242 patients were included. Median (quartile 1, quartile 3) LS values at pre-treatment and at SVR were 16.8 (12, 28) kPa and 12.0 (8.5, 19.3) kPa, respectively. Thirty-five SNPs and three genes reached suggestive association with LS changes from the moment of starting anti-HCV therapy to SVR. GO categories related to DNA packaging complex, DNA conformation change, chromosome organization and chromatin organization were significantly enriched. Our study reports possible genetic factors associated with LS changes during HCV-infection cure. In addition, our results suggest that processes related to DNA conformation are also involved in these changes.
PB MDPI
YR 2021
FD 2021-08-20
LK http://hdl.handle.net/10668/4346
UL http://hdl.handle.net/10668/4346
LA en
NO Corma-Gómez A, Macías J, Rivero A, Rivero-Juarez A, de Los Santos I, Reus-Bañuls S, et al. A Genome-Wide Association Study on Liver Stiffness Changes during Hepatitis C Virus Infection Cure. Diagnostics. 2021 Aug 20;11(8):1501
NO This work was supported by a grant from the Consejería de Salud de la Junta de An dalucía (project PI-0001/2017), and partially founded by the Instituto de Salud Carlos III (Projects PI16/01443 and PI19/01312), integrated in the national I+D+i 2013–2016, 2016–2019, and co-funded by the European Union (ERDF/ESF, “Investing in your future”), by the Spanish Network for AIDS investigation (RIS) (www.red.es/redes/inicio (accessed on 1 January 2021)) (RD16/0025/0040), as a part of the Nacional I+ D+I, ISCIII Subdirección General de Evaluación and the European Fund for Development of Regions (FEDER) and by GEHEP-SEIMC (GEHEP-011 project). J.A.P. has received a research extension grant from the Programa de Intensificación de la Actividad de Investigación del Servicio Nacional de Salud Carlos III (I3SNS). A.C.-G. has received a Río Hortega grant from the Instituto de Salud Carlos III (grant number CM19/00251). A.G.-S. is the recipient of a Miguel Servet Research Contract by Instituto de Salud Carlos III (CP18/00146). I.R. is the recipient of a P-FIS Research Contract by Instituto de Salud Carlos IIII (FI20/00215). A.Ruiz. is supported by national grants PI13/02434, PI16/01861 and PI19/01301. Acción Estratégica en Salud is integrated into the Spanish National R + D + I Plan and funded by ISCIII (Instituto de Salud Carlos III), Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER “Una manera de Hacer Europa”) and received support from the European Union/EFPIA Innovative Medicines Ini tiative Joint Undertaking ADAPTED and MOPEAD projects (Grants No. 115975 and 115985) and PREADAPT project (JPco-fuND-2. Grant number AC19/00097).
DS RISalud
RD Apr 12, 2025